• KLF6 Super-Enhancer Control of Human Adipogenesis

  2026-10-07

  Nguyen et al. identify a KLF6-proximal super-enhancer as an important regulatory hub during adipogenic differentiation of human adipose-derived stem cells. The study connects PPARγ-dependent enhancer activation, enhancer RNA, KLF6, HDAC3, and DLK1 into a mechanistic model that clarifies how adipogenic gene expression is established.

• Brain-to-Spinal Control of Mechanical Allodynia

  2026-10-07

  The 2023 Cell Reports study identifies a contralateral lateral parabrachial–hypothalamic–spinal circuit that regulates both the laterality and persistence of mechanical allodynia in mice. Its findings connect Oprm1 and Pdyn neuronal populations with spinal κ-opioid receptor signaling, providing a circuit-level framework for interpreting bilateral pain hypersensitivity and descending inhibition.

• DGLA–ACSL4 Ferroptosis in AML Cells

  2026-10-06

  Jiang and colleagues identify dihomo-γ-linolenic acid (DGLA) as a lipid-metabolic trigger of ferroptosis in acute myeloid leukemia cells and connect this effect to ACSL4-dependent remodeling of polyunsaturated fatty acid metabolism. The study combines targeted metabolomics, genetic perturbation, cell-based evidence, and an in vivo dietary model, while also highlighting the limits of translating ferroptosis findings from experimental AML systems to clinical treatment.

• Sucrose in Human Microglia Research: Evidence and Limits

  2026-10-06

  Sucrose can influence how biological samples are stabilized and interpreted, but it should not be mistaken for a demonstrated driver of microglial biology. This article places sucrose in the context of the human microglia transplantation model reported by Serneels et al., separating established findings from plausible methodological considerations.

• EDC.HCl Product Overview and Evidence Limits

  2026-10-05

  EDC.HCl is a water-soluble carbodiimide reagent listed by APExBIO for conceptual use in amide-bond-forming chemistry, peptide synthesis, and bioconjugation. No matched paper evidence is available for this product overview.

• Saracatinib: Interpreting Src Signaling Across Models

  2026-10-05

  Saracatinib (AZD0530) is examined here as a mechanistic perturbation tool for cancer biology and synaptic signaling research. This article connects Src-family kinase biology with the Reelin–Apoer2–SFK findings reported in PNAS while emphasizing evidence boundaries, model differences, and interpretation.

• How Imidazoline Antagonists Raise Insulin Release

  2026-10-04

  The 1992 study by Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than only by blocking adrenergic receptors. By combining insulin secretion measurements with 86Rb efflux and patch-clamp analyses, the paper linked pharmacological effects to β-cell ion-channel activity while also defining important limits of that interpretation.

• EZ Cap™ Human PTEN mRNA: Evidence Context

  2026-10-03

  This overview places EZ Cap™ Human PTEN mRNA within current cancer research on tumor suppressor gene mRNA and nanoparticle delivery. It distinguishes supplier-described molecular features from published preclinical evidence, emphasizing that nitric-oxide-mediated vascular barrier modulation has not yet been shown to deliver PTEN mRNA or restore PTEN signaling in humans.

• HNRNPU K181 Lactylation Rewires Cervical Cancer

  2026-10-02

  This Advanced Science study identifies HNRNPU lysine 181 lactylation as a non-histone regulatory event that links lactate accumulation to PHGDH expression, serine biosynthesis, and cervical cancer growth. Its combination of proteomic discovery, RNA-centered mechanistic analysis, and in vitro and in vivo validation provides a framework for studying how metabolic signals reshape post-transcriptional gene regulation.

• Exendin-4: From GLP-1 Mechanism to Access

  2026-10-01

  Exendin-4, also known as Exenatide in therapeutic contexts, is more than a GLP-1 receptor agonist: it is a mechanistic probe for cAMP signaling, beta cell performance, metabolic disease, and emerging access models. This thought-leadership article connects assay design with yeast-based production research while separating demonstrated evidence from translational opportunity.

• Phillygenin and Signaling in Diabetic Nephropathy

  2026-10-01

  The reference study shows that phillygenin protects against diabetic nephropathy by coordinating suppression of TLR4/MyD88/NF-κB-associated inflammation with restoration of PI3K/AKT/GSK3β signaling in podocytes and db/db mice. Its integrated cell, transcriptomic, biochemical, and animal design provides a mechanistic framework for evaluating renal injury, although the findings remain preclinical and do not establish direct molecular binding or clinical efficacy.

• FTSJ3 Loss, R-Loops, and Lung Cancer Chemosensitivity

  2026-09-30

  The reference study identifies FTSJ3 as a regulator of R-loop homeostasis and genome stability in lung cancer cells. Its depletion increases R-loop-associated DNA damage and enhances cisplatin sensitivity, supporting FTSJ3 as a potential biomarker and therapeutic vulnerability for further preclinical investigation.

• RUNX2 Epigenetic Repression Drives OS ICB Resistance

  2026-09-30

  This study identifies a RUNX2–NCOR1–HDAC3 repressor complex that suppresses enhancer activity in the type I interferon pathway and limits immune checkpoint blockade efficacy in osteosarcoma. Its findings support combining selective HDAC3 inhibition with anti-PD-1 therapy to restore cGAS–STING–IFN-I signaling while managing the compensatory induction of PD-L1 and PD-L2.

• LG 101506: Practical RXR Modulator Workflows

  2026-09-29

  Build reproducible RXR signaling assays with LG 101506, from reporter studies to pathway-focused cancer models. This workflow distinguishes direct receptor biology from hypothesis-generating applications in PD-L1 and triple-negative breast cancer research.

• Human iPSC Intestinal Organoids for Pharmacokinetics

  2026-09-29

  The 2025 reference study establishes a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. These organoids can be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated CYP and transporter activities, creating a more human-relevant platform for pharmacokinetic studies.

8627 records 1/576 page Next 12345 下5页 Last page